HSP90 manages the ends

Trends in Biochemical Sciences

Volumn 35, Issue 7, 2010, Pages 384-391

  DeZwaan, Diane C ^a   Freeman, Brian C ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CHAPERONE; DNA; GRN 163L; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 82; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN CDC13; RHPS 4; TANESPIMYCIN; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; EUKARYOTE; HOMEOSTASIS; MICROENVIRONMENT; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; TELOMERE; CHEMISTRY; HUMAN; METABOLISM;

DNA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; TELOMERE;

EID: 77954315404     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2010.02.005     Document Type: Review

References (76)

1. Misteli T. The concept of self-organization in cellular architecture. J. Cell Biol. 2001, 155:181-185.
2. Freeman B.C., Yamamoto K.R. Continuous recycling: a mechanism for modulatory signal transduction. Trends Biochem. Sci. 2001, 26:285-290.
3. DeZwaan D.C., Freeman B.C. HSP90: the Rosetta stone for protein dynamics?. Cell Cycle 2008, 7:1006-1012.
4. Gilson E., Géli V. How telomeres are replicated. Nat. Rev. Mol. Cell Biol. 2007, 8:825-838.
5. Shay J.W., Wright W.E. Telomerase activity in human cancer. Curr. Opin. Oncol. 1996, 8:66-71.
6. Hemann M.T., et al. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107:67-77.
7. Shore D., Bianchi A. Telomere length regulation: coupling DNA end processing to feedback regulation of telomerase. EMBO J. 2009, 28:2309-2322.
8. Marcand S., et al. Cell cycle restriction of telomere elongation. Curr. Biol. 2000, 10:487-490.
9. Teixeira M.T., et al. Telomere length homeostasis is achieved via a switch between telomerase extendible and -nonextendible states. Cell 2004, 117:323-335.
10. Ellis R.J., van der Vies S.M. Molecular chaperones. Annu. Rev. Biochem. 1991, 60:321-347.
11. Hendrick J.P., Hartl F.U. Molecular chaperone functions of heat-shock proteins. Annu. Rev. Biochem. 1993, 62:349-384.
12. Wegele H., et al. HSP70 and HSP90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 2004, 151:1-44.
13. Mayer M.P., Bukau B. HSP70 chaperones: cellular functions and molecular mechanism. Cell Mol. Life Sci. 2005, 62:670-684.
14. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the HSP90/HSP70-based chaperone machinery. Exp. Biol. Med. 2003, 228:111-133.
15. Millson S.H., et al. A two-hybrid screen of the yeast proteome for HSP90 interactors uncovers a novel HSP90 chaperone requirement in the activity of a stress-activated mitogen-activated protein kinase, Slt2p (Mpk1p). Euk. Cell 2005, 4:849-860.
16. Zhao R., et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the HSP90 chaperone. Cell 2005, 120:715-727.
17. McClellan A.J., et al. Diverse cellular functions of the HSP90 molecular chaperone uncovered using systems approaches. Cell 2007, 131:121-135.
18. Johnson J.L., Brown C. Plasticity of the HSP90 chaperone machine in divergent eukaryotic organisms. Cell Stress Chaperones 2009, 14:83-94.
19. Ziemieowicz A., et al. Calf thymus Hsc70 and Hsc40 can substitute for DnaK and DnaJ function in protein renaturation but not in bacteriophage DNA replication. FEBS Lett. 2001, 507:11-15.
20. Ellis R.J. Protein misassembly: macromolecular crowding and molecular chaperones. Adv. Exp. Med. Biol. 2007, 594:1-13.
21. Shaknovich R., et al. Conformational activation of a basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine HSP90 (HSP84). Mol. Cell Biol. 1992, 12:5059-5068.
22. Freeman B.C., Yamamoto K.R. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002, 296:2232-2235.
23. Müller L., et al. HSP90 regulates the activity of wild type p53 under physiological and elevated temperatures. J. Biol. Chem. 2004, 279:48846-48854.
24. Stavreva D.A., et al. Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol. Cell Biol. 2004, 24:2682-2697.
25. Walerych D., et al. HSP90 chaperones wild-type p53 tumor suppressor protein. J. Biol. Chem. 2004, 279:48836-48845.
26. Toogun O.A., et al. The p23 molecular chaperone promotes functional telomerase complexes through DNA dissociation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5765-5770.
27. Toogun O.A., et al. The HSP90 molecular chaperone modulates multiple telomerase activities. Mol. Cell Biol. 2008, 28:457-467.
28. DeZwaan D.C., et al. The Hsp82 molecular chaperone promotes a switch between unextendable and extendable telomere states. Nat. Struct. Mol. Biol. 2009, 16:711-716.
29. Konieczny I., Zylicz M. Role of bacterial chaperones in DNA replication. Genet. Eng. 1999, 21:95-111.
30. Richter K., et al. The cellular world according to HSP90. Nat. Struct. Mol. Biol. 2007, 14:90-94.
31. Hager G.L., et al. Transcription dynamics. Mol. Cell 2009, 35:741-753.
32. Holt S.E., et al. Functional requirement of p23 and HSP90 in telomerase complexes. Genes Dev. 1999, 13:817-826.
33. Britt-Compton B., et al. Short telomeres are preferentially elongated by telomerase in human cells. FEBS Lett. 2009, 583:3076-3080.
34. Cohn M., Blackburn E.H. Telomerase in yeast. Science 1995, 269:396-400.
35. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989, 59:521-529.
36. Forsythe H.L., et al. Stable association of HSP90 and p23, but Not HSP70, with active human telomerase. J. Biol. Chem. 2001, 276:15571-15574.
37. Grandin N., Charbonneau M. HSP90 levels affect telomere length in yeast. Mol. Genet. Genomics 2001, 265:126-134.
38. Ghaemmaghami S., et al. Global analysis of protein expression in yeast. Nature 2003, 425:737-741.
39. Beckmann R.P., et al. Interaction of HSP70 with newly synthesized proteins: implications for protein folding and assembly. Science 1990, 248:850-854.
40. Bukau B., Walker G.C. Cellular defects caused by deletion of the Escherichia coli dnaK gene indicate roles for heat shock protein in normal metabolism. J. Bacteriol. 1989, 171:2337-2346.
41. Deuerling E., et al. Trigger factor and DnaK cooperate in folding of newly synthesized proteins. Nature 1999, 400:693-696.
42. Keppler B.R., et al. The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J. Biol. Chem. 2006, 281:19840-19848.
43. Pennock E., et al. Cdc13 delivers separate complexes to the telomere for end protection and replication. Cell 2001, 104:387-396.
44. Grandin N., et al. Stn1, a new Sacchromyces cerevisiae protein, is implicated in telomere size regulation in association with Cdc13. Genes Dev. 1997, 11:512-527.
45. Shampay J., Blackburn E.H. Generation of telomere-length heterogeneity in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:534-538.
46. Blackburn E.H., et al. Recognition and elongation of telomeres by telomerase. Genome 1989, 31:553-560.
47. Osterhage J.L., et al. Proteasome-dependent degradation of Est1p regulates the cell cycle-restricted assembly of telomerase in Saccharomyces cerevisiae. Nat. Struct. Mol. Biol. 2006, 13:720-728.
48. Li S., et al. Cdk1-dependent phosphorylation of Cdc13 coordinates telomere elongation during cell-cycle progression. Cell 2009, 136:50-61.
49. Nakada D., et al. ATM-related Tel1 associates with double-strand breaks through an Xrs2-dependent mechanism. Genes Dev. 2003, 17:1957-1962.
50. Tseng S.F., et al. The telomerase-recruitment domain of the telomere binding protein Cdc13 is regulated by Mec1p/Tel1p-dependent phosphorylation. Nucleic Acids Res. 2006, 34:6327-6336.
51. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
52. Akalin A., et al. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res. 2001, 61:4791-4796.
53. Oxelmark E., et al. The co-chaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion. Mol. Cell Biol. 2006, 26:5205-5213.
54. Elmore L.W., et al. Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas. Oncol. Rep. 2008, 20:613-617.
55. McDowell C.L., et al. Expression of HSP90 chaperone [corrected] proteins in human timor tissue. Int. J. Biol. Macromol. 2009, 45:310-314.
56. Flores I., et al. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell Biol. 2006, 18:254-260.
57. Cech T.R. Beginning to understand the end of the chromosome. Cell 2004, 116:273-279.
58. Teng S.C., et al. Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J. Biol. Chem. 2004, 279:14649-14655.
59. Lee C.L., et al. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 2003, 3:2472-2486.
60. Shervington A., et al. Glioma: what is the role of c-Myc, HSP90 and telomerase?. Mol. Cell Biochem 2006, 283:1-9.
61. Becker B., et al. Induction of HSP90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 2004, 13:27-32.
62. Mitsiades C.S., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
63. Shammas M.A., et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22:1410-1418.
64. Villa R., et al. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis 2003, 24:851-859.
65. Cookson J.C., et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quinto[4,3,2,k1]acridinium methosulfate (RHPS4) in vitro; activity in human tumour cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 2005, 68:1551-1558.
66. Kamal A., et al. A high-affinity conformation of HSP90 confers tumour selectivity on HSP90 inhibitors. Nature 2003, 425:407-410.
67. Daozhen C., et al. Synthesis of (131)I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin ([(131)I]iodo-17-AAG) and its biodistribution in mice. Cancer Biother. Radiopharm. 2007, 22:607-612.
68. Prigogine I., Nicolis G. Biological order, structure and instabilities. Q. Rev. Biophys. 1971, 4:107-148.
69. Whitesell L., Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol. 1996, 10:705-712.
70. Prodromou C., et al. Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone. Cell 1997, 90:65-75.
71. Wandinger S.K., et al. The HSP90 chaperone machinery. J. Biol. Chem. 2008, 283:18473-18477.
72. Kim Y.S., et al. Update on HSP90 inhibitors in clinical trial. Curr. Top. Med. Chem. 2009, 9:1479-1492.
73. Powers M.V., Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007, 581:3758-3769.
74. Hwang M., et al. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 2009, 16:3081-3092.
75. Chen H., et al. Strategies targeting telomerase inhibition. Mol. Biotechnol. 2009, 41:194-199.
76. Burger A.M. Highlights in experimental therapeutics. Cancer Lett. 2007, 245:11-21.